{"id":"xr-tacrolimus-qd-mmf-bid-then-mmf-qd","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Neurotoxicity (tremor, headache)"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Gastrointestinal disturbance (diarrhea, nausea)"},{"rate":null,"effect":"Infections"},{"rate":null,"effect":"Leukopenia"}]},"_chembl":{"chemblId":"CHEMBL3400969","moleculeType":"Small molecule","molecularWeight":"413.48"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"XR-tacrolimus is an extended-release calcineurin inhibitor that blocks T-cell activation by inhibiting calcineurin-dependent cytokine production. Mycophenolate mofetil (MMF) is an inosine monophosphate dehydrogenase inhibitor that selectively suppresses lymphocyte proliferation. Together, they provide dual immunosuppression for post-transplant maintenance therapy, with MMF dosing reduced over time as tacrolimus levels stabilize.","oneSentence":"This combination regimen suppresses T-cell activation and proliferation to prevent organ transplant rejection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:16:21.460Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ transplant rejection (renal, cardiac, hepatic transplantation)"}]},"trialDetails":[{"nctId":"NCT06354179","phase":"PHASE4","title":"Evaluation of the Benefits of Administering Immunosuppressive Drugs as Single Daily Doses Over the First Year After Liver Transplantation (EASY)","status":"RECRUITING","sponsor":"University Hospital, Limoges","startDate":"2025-04-15","conditions":"Liver Transplantation, Immunosuppression","enrollment":162}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"XR-tacrolimus QD + MMF BID then MMF QD","genericName":"XR-tacrolimus QD + MMF BID then MMF QD","companyName":"University Hospital, Limoges","companyId":"university-hospital-limoges","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination regimen suppresses T-cell activation and proliferation to prevent organ transplant rejection. Used for Prevention of organ transplant rejection (renal, cardiac, hepatic transplantation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}